APONTIS PHARMA AG (APPH.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:APPH - DE000A3CMGM5 - Common Stock
11 EUR
0 (0%)
We assign a fundamental rating of 5 out of 10 to APPH. APPH was compared to 52 industry peers in the Pharmaceuticals industry. APPH has a great financial health rating, but its profitability evaluates not so good. APPH has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
APPH had positive earnings in the past year.
In the past year APPH has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: APPH reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: APPH reported negative operating cash flow in multiple years.
1.2 Ratios
APPH has a worse Return On Assets (1.70%) than 60.71% of its industry peers.
APPH's Return On Equity of 2.34% is on the low side compared to the rest of the industry. APPH is outperformed by 60.71% of its industry peers.
The Return On Invested Capital of APPH (2.01%) is worse than 64.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.7% | ||
| ROE | 2.34% | ||
| ROIC | 2.01% |
ROA(3y)-4.37%
ROA(5y)-3.69%
ROE(3y)-9.26%
ROE(5y)-12.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
APPH has a Profit Margin (1.55%) which is in line with its industry peers.
APPH has a Operating Margin of 2.60%. This is in the lower half of the industry: APPH underperforms 64.29% of its industry peers.
In the last couple of years the Operating Margin of APPH has declined.
APPH's Gross Margin of 57.16% is on the low side compared to the rest of the industry. APPH is outperformed by 67.86% of its industry peers.
APPH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.6% | ||
| PM (TTM) | 1.55% | ||
| GM | 57.16% |
OM growth 3Y-32.83%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.69%
GM growth 5Y-4.61%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), APPH is destroying value.
Compared to 1 year ago, APPH has about the same amount of shares outstanding.
Compared to 5 years ago, APPH has less shares outstanding
APPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
APPH has an Altman-Z score of 6.01. This indicates that APPH is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.01, APPH belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
There is no outstanding debt for APPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.01 |
ROIC/WACC0.28
WACC7.19%
2.3 Liquidity
APPH has a Current Ratio of 6.82. This indicates that APPH is financially healthy and has no problem in meeting its short term obligations.
APPH has a better Current ratio (6.82) than 98.21% of its industry peers.
A Quick Ratio of 4.86 indicates that APPH has no problem at all paying its short term obligations.
The Quick ratio of APPH (4.86) is better than 98.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.82 | ||
| Quick Ratio | 4.86 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 106.98% over the past year.
APPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.12%.
APPH shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.89% yearly.
EPS 1Y (TTM)106.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
Revenue 1Y (TTM)31.12%
Revenue growth 3Y-1.8%
Revenue growth 5Y3.89%
Sales Q2Q%14.55%
3.2 Future
APPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 128.83% yearly.
APPH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.31% yearly.
EPS Next Y393.69%
EPS Next 2Y194.54%
EPS Next 3Y128.83%
EPS Next 5YN/A
Revenue Next Year21.53%
Revenue Next 2Y20.18%
Revenue Next 3Y18.69%
Revenue Next 5Y15.31%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 122.22, the valuation of APPH can be described as expensive.
APPH's Price/Earnings ratio is a bit more expensive when compared to the industry. APPH is more expensive than 67.86% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.51. APPH is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 11.20, which indicates a very decent valuation of APPH.
Based on the Price/Forward Earnings ratio, APPH is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
APPH is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.13, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 122.22 | ||
| Fwd PE | 11.2 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of APPH indicates a slightly more expensive valuation: APPH is more expensive than 69.64% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 30.66 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as APPH's earnings are expected to grow with 128.83% in the coming years.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y194.54%
EPS Next 3Y128.83%
5. Dividend
5.1 Amount
APPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:APPH (11/14/2025, 7:00:00 PM)
11
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners38.49%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap93.50M
Revenue(TTM)48.47M
Net Income(TTM)750.00K
Analysts82.86
Price Target13.77 (25.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)35%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)71.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 122.22 | ||
| Fwd PE | 11.2 | ||
| P/S | 1.93 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.92 | ||
| P/tB | 7.19 | ||
| EV/EBITDA | 30.66 |
EPS(TTM)0.09
EY0.82%
EPS(NY)0.98
Fwd EY8.93%
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS5.7
BVpS3.76
TBVpS1.53
PEG (NY)0.31
PEG (5Y)N/A
Graham Number2.76
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.7% | ||
| ROE | 2.34% | ||
| ROCE | 3.08% | ||
| ROIC | 2.01% | ||
| ROICexc | 2.01% | ||
| ROICexgc | 3.75% | ||
| OM | 2.6% | ||
| PM (TTM) | 1.55% | ||
| GM | 57.16% | ||
| FCFM | N/A |
ROA(3y)-4.37%
ROA(5y)-3.69%
ROE(3y)-9.26%
ROE(5y)-12.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-32.09%
ROICexgc growth 5YN/A
ROICexc growth 3Y-36.79%
ROICexc growth 5YN/A
OM growth 3Y-32.83%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.69%
GM growth 5Y-4.61%
F-Score5
Asset Turnover1.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 214.53% | ||
| Cap/Sales | 7.92% | ||
| Interest Coverage | 9.69 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.82 | ||
| Quick Ratio | 4.86 | ||
| Altman-Z | 6.01 |
F-Score5
WACC7.19%
ROIC/WACC0.28
Cap/Depr(3y)153.48%
Cap/Depr(5y)119.91%
Cap/Sales(3y)6.51%
Cap/Sales(5y)4.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)106.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
EPS Next Y393.69%
EPS Next 2Y194.54%
EPS Next 3Y128.83%
EPS Next 5YN/A
Revenue 1Y (TTM)31.12%
Revenue growth 3Y-1.8%
Revenue growth 5Y3.89%
Sales Q2Q%14.55%
Revenue Next Year21.53%
Revenue Next 2Y20.18%
Revenue Next 3Y18.69%
Revenue Next 5Y15.31%
EBIT growth 1Y113.36%
EBIT growth 3Y-34.04%
EBIT growth 5YN/A
EBIT Next Year419.89%
EBIT Next 3Y131.3%
EBIT Next 5YN/A
FCF growth 1Y16.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.68%
OCF growth 3YN/A
OCF growth 5YN/A
APONTIS PHARMA AG / APPH.DE FAQ
Can you provide the ChartMill fundamental rating for APONTIS PHARMA AG?
ChartMill assigns a fundamental rating of 5 / 10 to APPH.DE.
Can you provide the valuation status for APONTIS PHARMA AG?
ChartMill assigns a valuation rating of 4 / 10 to APONTIS PHARMA AG (APPH.DE). This can be considered as Fairly Valued.
What is the profitability of APPH stock?
APONTIS PHARMA AG (APPH.DE) has a profitability rating of 1 / 10.
What is the expected EPS growth for APONTIS PHARMA AG (APPH.DE) stock?
The Earnings per Share (EPS) of APONTIS PHARMA AG (APPH.DE) is expected to grow by 393.69% in the next year.